secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001193125-25-281522
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA reports Q3 R&D $4.9M, cash burn $22.1M; Phase 3 MCC trial underway
-------------------------------------------------------------------------

- Phase 3 IFx-2.0 trial for MCC under SPA enrollment ongoing; topline results expected Q1 2027.
- R&D expenses $4.9M (Q3 2025) vs $2.9M (Q3 2024); 9-month net cash outflow $22.1M vs $12.1M.
- DOR technology selected for oral presentation at ASH 2025 Annual Meeting in December.
- Appointed Dr. Michael Turner as Vice President of Immunology in November 2025.
- Filed $50M ATM facility in November 2025; not yet effective.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000119312525281522/0001193125-25-281522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000119312525281522/hura-20251114.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-281522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer